Form 8-K - Current report:
SEC Accession No. 0001558370-25-011925
Filing Date
2025-09-08
Accepted
2025-09-08 16:05:16
Documents
13
Period of Report
2025-09-06
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20250906x8k.htm   iXBRL 8-K 40728
2 EX-10.1 adap-20250906xex10d1.htm EX-10.1 141248
  Complete submission text file 0001558370-25-011925.txt   321237

Data Files

Seq Description Document Type Size
3 EX-101.SCH adap-20250906.xsd EX-101.SCH 3896
4 EX-101.LAB adap-20250906_lab.xml EX-101.LAB 15970
5 EX-101.PRE adap-20250906_pre.xml EX-101.PRE 10789
15 EXTRACTED XBRL INSTANCE DOCUMENT adap-20250906x8k_htm.xml XML 4866
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 251300040
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)